Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $167 from $163 and keeps an Overweight rating on the shares after the company presented data from the Xywav Phase 4 DUET study evaluating low-sodium oxybate at World Sleep Singapore. The data show that oxybates are differentiated and can directly improve sleep architecture, says the analyst, who increased the firm’s Xywav market share estimates in FY28-33.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals announces new evidence, Phase 4 data on Xywav
- Avadel says court requires 3.85% of Lumryz sales go to Jazz
- Jazz Pharmaceuticals’ ZW25 Study Update: A Potential Game-Changer in Cancer Treatment
- Jazz Pharmaceuticals’ Modeyso recommended for glioma by NCCN Guidelines
- Kohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by Analysts